ストックスクリーナーアプリを入手
8.53
1.61%
-0.14
アフターアワーズ：
8.48
-0.05
-0.59%
Actuate Therapeutics Inc (ACTU) 最新ニュース
Actuate Therapeutics Inc. Stages Intraday Comeback — Trend ChangeStock Surge & Verified Entry Point Detection - 선데이타임즈
Short interest data insights for Actuate Therapeutics Inc.July 2025 PostEarnings & Short-Term Swing Trade Alerts - Newser
Detecting price anomalies in Actuate Therapeutics Inc. with AI2025 Price Targets & Free Real-Time Volume Trigger Notifications - Newser
Forecasting Actuate Therapeutics Inc. price range with options dataJuly 2025 Market Mood & Low Drawdown Investment Strategies - Newser
How institutional ownership impacts Actuate Therapeutics Inc. stockJuly 2025 EndofMonth & Risk Adjusted Buy and Sell Alerts - Newser
Why Actuate Therapeutics Inc. is moving todayJuly 2025 Institutional & Fast Gain Stock Trading Tips - Newser
Regression analysis insights on Actuate Therapeutics Inc. performanceWeekly Loss Report & Daily Chart Pattern Signal Reports - Newser
Will Actuate Therapeutics Inc. stock split in the near future2025 Retail Activity & Weekly High Momentum Picks - Newser
Is a relief rally coming for Actuate Therapeutics Inc. holdersJuly 2025 Outlook & AI Optimized Trade Strategies - Newser
What the charts say about Actuate Therapeutics Inc. todayMarket Growth Summary & Daily Chart Pattern Signals - Newser
Published on: 2025-08-13 05:24:46 - 선데이타임즈
Should you hold or exit Actuate Therapeutics Inc. nowLong Term Stock Growth Plan Suggestions - Newser
Smart tools for monitoring Actuate Therapeutics Inc.’s price actionHistorical Stock Summary and ROI Review - Newser
Why Actuate Therapeutics Inc. stock attracts strong analyst attentionFree Proven Entry Plan With Low Risk Trade - Newser
Has Actuate Therapeutics Inc. found a price floorProfitable Trading Blueprint with Entry Zones - Newser
Will Actuate Therapeutics Inc. stock recover after recent dropChart Scanner for Swing Trade Timing - Newser
Risk adjusted return profile for Actuate Therapeutics Inc. analyzedChart Scanner for Swing Trade Timing - Newser
Backtesting results for Actuate Therapeutics Inc. trading strategiesDaily Market Movers Screener with Filters - Newser
Tick level data insight on Actuate Therapeutics Inc. volatilityChart Signal and Short-Term Forecast Tracker - Newser
Actuate Therapeutics Inc. stock momentum explainedTechnical Screener for High Growth Stocks - Newser
Fermented Stevia Extract Shows Promise in Fighting Pancreatic Cancer in Lab Tests - AInvest
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer - The Globe and Mail
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - The Globe and Mail
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - The Globe and Mail
What makes Actuate Therapeutics Inc. stock price move sharplyRSI and MACD Signal Summary with Trends - Newser
Actuate Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingInvestment Timing Strategy with Market Filters - Newser
Hillman Solutions Corp shares rise 3.41% intraday after Actuate Therapeutics announced a clinical trial collaboration with UPMC Hillman Cancer Center. - AInvest
Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial - TipRanks
Actuate Therapeutics to collaborate with Incyte Corporation on clinical trials - MarketScreener
Actuate Therapeutics To Collaborate with Incyte Corporation - GlobeNewswire
Actuate Therapeutics, Inc. to Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - MarketScreener
Does Actuate Therapeutics Inc. fit your quant trading modelExit Strategy Guide With Risk Control Plan - Newser
Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc - Barchart.com
Candlestick Signal Suggests Reversal in Actuate Therapeutics Inc.Fast Exit and Entry Strategy Guide Offered - beatles.ru
What drives Actuate Therapeutics Inc. stock priceBuild wealth faster with consistent investment plans - Jammu Links News
Actuate Therapeutics Inc. Stock Analysis and ForecastBuild a diversified portfolio for steady growth - Jammu Links News
What is the dividend policy of Actuate Therapeutics Inc. stockAchieve consistent profits with proven strategies - Jammu Links News
Is Actuate Therapeutics Inc. a growth stock or a value stockFree Expert Stock Watchlist - Jammu Links News
Is it the right time to buy Actuate Therapeutics Inc. stockAchieve superior returns with professional insights - Jammu Links News
Is Actuate Therapeutics Inc. a good long term investmentCapitalize on fast-growing stocks today - Jammu Links News
What are analysts’ price targets for Actuate Therapeutics Inc. in the next 12 monthsSuperior portfolio returns - Jammu Links News
What catalysts could drive Actuate Therapeutics Inc. stock higher in 2025Invest confidently with real-time market updates - Jammu Links News
What MACD signals say about Actuate Therapeutics Inc.7-Day Equity Return Range Forecast Model - Newser
1.67%
大文字化:
|
ボリューム (24 時間):